Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Glioma × lenvatinib × Clear all

Phase

Phase 2 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Hepatocellular 52 Cholangiocarcinoma 18 Carcinoma, Renal Cell 13 Biliary Tract Neoplasms 10 Stomach Neoplasms 8 Thyroid Neoplasms 6 Parkinson Disease 4, Autosomal Dominant Lewy Body 6 Neoplasms 6 Endometrial Neoplasms 6 Uterine Cervical Neoplasms 5 Recurrence 4 Ovarian Neoplasms 4 Melanoma 4 Carcinoma, Non-Small-Cell Lung 4 Thyroid Carcinoma, Anaplastic 3 Thyroid Cancer, Papillary 3 Squamous Cell Carcinoma of Head and Neck 3 Small Cell Lung Carcinoma 3 Neuroendocrine Tumors 3 Neoplasm Metastasis 3 Liver Neoplasms 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Vulvar Neoplasms 2 Uveal Melanoma 2 Triple Negative Breast Neoplasms 2 Solid Tumors 2 Pancreatic Neoplasms 2 Mesothelioma, Malignant 2

Interventions

Temozolomide 59 Bevacizumab 37 Radiotherapy 19 Magnetic Resonance Spectroscopy 18 Irinotecan 16 Carboplatin 10 Specimen Handling 9 Carmustine 9 olaparib 6 X-Rays 6 Surgical Procedures, Operative 6 Phantoms, Imaging 6 Cyclophosphamide 6 Thalidomide 5 Nuclear Medicine Department, Hospital 5 Nivolumab 5 Biopsy 5 trametinib 4 pembrolizumab 4 Radiation 4 Lomustine 4 Everolimus 4 Cisplatin 4 Aminolevulinic Acid 4 sargramostim 3 poly ICLC 3 palbociclib 3 ivosidenib 3 fluorodopa F 18 3 erdafitinib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01137604 2022-09-29

A Study in Subjects With Recurrent Malignant Glioma

Eisai Inc.

Phase 2 Completed

151 enrolled 17 charts

Glioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡